[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The 95th Hospital of Putian，Putian, Fujian, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652818","metformin-dapagliflozin-effects-on-igf-1-in-male-t2dm-with-masld-100652818",false,"NCT07778719","Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD","Effects of Metformin Combined With Dapagliflozin on Serum IGF-1 Levels in Male Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease","MDEITM","Inclusion Criteria:\n\n1. Males aged 30-60 years;\n2. Meeting the WHO diagnostic criteria for type 2 diabetes mellitus, with HbA1c levels between 7.0% and 10.0%;\n3. Having received a stable dose of metformin (≥1500 mg\u002Fday or the maximum tolerated dose) as monotherapy for at least 8 weeks;\n4. Meeting the diagnostic criteria for MASLD: Controlled Attenuation Parameter (CAP) value ≥248 dB\u002Fm detected, with the presence of at least one cardiometabolic risk factor;\n5. No prior use of SGLT2 inhibitors, insulin secretagogues, insulin, or GLP-1 receptor agonists;\n6. Willing to participate voluntarily and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus or other specific types of diabetes;\n2. Weekly alcohol intake exceeding 210g for males;\n3. Concomitant chronic liver diseases (viral hepatitis, autoimmune liver disease, Wilson's disease, hemochromatosis, etc.);\n4. Known pituitary or hypothalamic diseases affecting the GH-IGF-1 axis;\n5. Previous or current use of GH preparations or IGF-1 preparations;\n6. Baseline estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73m²;\n7. Previous diagnosis of cardiovascular diseases (coronary heart disease, stroke, heart failure) or severe liver diseases (decompensated cirrhosis);\n8. Active malignant tumors;\n9. Allergy to dapagliflozin or similar drugs;\n10. Use of medications affecting IGF-1 levels (such as oral estrogens, high-dose glucocorticoids) within the past 3 months;\n11. Diabetic ketoacidosis, severe infection, or surgical stress within 1 month prior to enrollment.","MALE","30 Years","60 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a 3-month, single-center, prospective, randomized, parallel-controlled, open-label trial investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD). A total of 84 eligible male patients (aged 30-60 years, HbA1c 7.0%-10.0%, CAP ≥248 dB\u002Fm, on stable metformin monotherapy for ≥8 weeks) will be randomized 1:1 to either continue metformin alone or receive metformin plus dapagliflozin 10 mg\u002Fday for 12 weeks. The primary endpoint is the change in serum IGF-1 from baseline to 3 months between groups. Secondary endpoints include changes in hepatic steatosis (CAP), liver stiffness (LSM), FIB-4 index, metabolic parameters, and safety outcomes. The study aims to determine whether adding dapagliflozin to metformin can restore the suppressed GH-IGF-1 axis and provide mechanistic insights into its hepatoprotective effects.",[28,29],"Type 2 Diabetes","Metabolic Dysfunction-Associated Steatotic Liver Disease",[31,32,33,34,29],"Dapagliflozin","Metformin","Serum IGF-1","Type 2 Diabetes Mellitus","NOT_YET_RECRUITING","2026-08-19",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":22},"2026-10-01",{"date":43,"type":22},"2027-12-11",{"name":45,"class":46},"The 95th Hospital of Putian，Putian, Fujian, China","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100652296","rowing-and-cycling-reduce-inflammation-in-early-stage-type-2-diabetes-100652296","NCT07769840","Rowing and Cycling Reduce Inflammation in Early-Stage Type 2 Diabetes","Effects of Different Modes of Rowing Combined With Cycling Exercise on Inflammatory Markers in Newly Diagnosed Type 2 Diabetes Patients","Inclusion Criteria:\n\n1. Age between 18-60 years, no gender limited;\n2. Meeting the WHO 1999 diagnostic criteria for T2DM, with a diagnosis time ≤12 months;\n3. Not having received hypoglycemic drug treatment (or only lifestyle intervention, and stopped medication ≥4 weeks before enrollment);\n4. Fasting blood glucose 7.0-13.9 mmol\u002FL, glycated hemoglobin (HbA1c) 6.5%-10.0%;\n5. No regular exercise in the past 3 months (less than 2 times per week of moderate or higher intensity exercise, each \\\u003C30 minutes);\n6. Voluntarily signing the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 diabetes, gestational diabetes, or other special types of diabetes;\n2. Severe cardiovascular or cerebrovascular diseases (NYHA heart function ≥III, recent myocardial infarction or unstable angina);\n3. Uncontrolled hypertension (resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);\n4. Severe liver or kidney dysfunction (ALT\u002FAST ≥3 times the upper limit of normal, or eGFR\\\u003C60 mL\u002Fmin\u002F1.73m²);\n5. Severe diabetic complications (such as proliferative retinopathy, severe neuropathy, diabetic foot);\n6. Pregnant or breastfeeding women;\n7. Mental illness or cognitive impairment that prevents compliance with the study;\n8. Stress events such as infection, trauma, or surgery in the past month;\n9. Participation in other interventional clinical studies;\n10. Musculoskeletal diseases of the upper or lower limbs that affect rowing machine or bicycle exercise.","ALL","18 Years",{"count":58,"type":22},120,[25],"This multicenter randomized controlled trial evaluates the short-term (7-day) effects of different rowing-cycling exercise regimens on postprandial glycemic excursions in newly diagnosed type 2 diabetes patients (aged 18-60 years, diagnosis ≤12 months, drug-naïve). A total of 120 participants will be randomized into five groups: control, moderate-intensity continuous cycling, high-intensity interval rowing, and standard combined exercise (rowing + cycling, 50 min). The primary outcome is inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-1ra, IL-10, hs-CRP), body Composition and functional Indicators. Secondary outcomes include change in continuous glucose monitoring-derived glycemic variability (CONGA), and time-in-range. Mixed-effects models will quantify dose-response relationships and identify key effect modifiers (e.g., age). This study aims to establish an evidence-based precision exercise prescription for early-stage type 2 diabetes management.",[62],"Diabetes","2026-08-12",{"date":65,"type":39},"2026-08-18",{"date":41,"type":22},{"date":68,"type":22},"2028-12-11",{"name":45,"class":46},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":55,"minAge":56,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":47},"100650329","coq10-effects-on-mdm-liver-fat-via-fibrotouchi-100650329","NCT07748130","CoQ10 Effects on MDM Liver Fat Via FibroTouchI.","The Effect of Coenzyme Q10 on Quantitative Changes in Hepatic Fat in Patients With Mitochondrial Diabetes","1\\. Mitochondrial Diabetes Group\n\nInclusion Criteria:\n\n1. Confirmed as a carrier of the mitochondrial DNA m.3243A\\>G mutation through genetic testing;\n2. Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria);\n3. Aged between 18 and 70 years;\n4. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 or type 2 diabetes (not caused by mitochondrial gene mutations);\n2. Comorbid with viral hepatitis, drug-induced hepatitis, alcoholic liver disease, Wilson's disease, or other specific diseases that can lead to fatty liver;\n3. Severe cardiac, pulmonary, or renal insufficiency;\n4. Pregnant or lactating women;\n5. Having used coenzyme Q10 or other mitochondrial-targeted drugs within the past 3 months;\n6. Having contraindications to MRI examination;\n7. Having experienced infection, surgery, or major trauma within the past 4 weeks.\n\nWithdrawal\u002FDropout Criteria:\n\n1. The subject withdraws informed consent;\n2. The occurrence of serious adverse events;\n3. Loss to follow-up;\n4. Medication adherence that continued participation in \\\u003C 80%;\n5. The researcher believes the study is not in the best interest of the subject. 2. Type 1 Diabetes Control Group\n\nInclusion Criteria:\n\n1. Meeting the diagnostic criteria for type 1 diabetes, with positive islet autoantibodies (GAD, IA-2, ICA, etc.);\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group. 3. Healthy Adult Control Group\n\nInclusion Criteria:\n\n1. No history of diabetes, with fasting blood glucose \\\u003C 5.6 mmol\u002FL and HbA1c \\\u003C 5.7%;\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group.",true,"70 Years",{"count":80,"type":22},30,[25],"Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg\u002Fday) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.",[84],"Mitochondrial Diabetes","2026-07-31",{"date":87,"type":39},"2026-08-05",{"date":89,"type":22},"2026-09",{"date":91,"type":22},"2027-12",{"name":45,"class":46},""]